Feed SAN.PA
SA

Sanofi

SAN.PA · PAR

74.13 € -0.62% (-0.46 €)
1M -4.71%
Market Cap 90.0B €
P/E Ratio 22.74x
Div. Yield 5.50%
ROE 5.52%

Bulios Fair Price

41.53 €

44.0% downside

Current Price

74.13 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SAN.PA is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
77 /100
Cheap
P/E 22.74x
EV/EBITDA 13.00x
P/S 1.84x
Growth
28 /100
Declining
EPS growth 1.32%
Rev. growth 2.68%
FCF growth 2.59%
Profitability
86 /100
Strong
Gross margin 72.77%
Net margin 8.09%
Op. margin 20.58%
Quality
33 /100
Poor
ROIC 7.41%
ROE 5.52%
ROA 3.07%
Debt
71 /100
Low
Debt/Equity 0.34x
Current ratio 0.99x
Int. coverage 8.44x
Stability
65 /100
Moderate
Beta 0.28x
Rev. volatility 4.65%
EPS volatility 40.65%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SAN.PA
Online

About the company

Sanofi (SNY) is a global pharmaceutical company headquartered in France. It focuses on research, development, manufacturing, and distribution of medicinal products in various therapeutic areas. Sanofi has a broad portfolio of pharmaceutical products, including medications for cardiovascular diseases, respiratory diseases, diabetes, immune system disorders, and more. The company is known for its innovative drugs and vaccines that contribute to the improvement of global healthcare. With a long history, extensive research efforts, and a strong global presence, Sanofi has become a key player in the pharmaceutical market. Sanofi (SNY) shares represent an attractive investment opportunity for investors seeking a stable and promising investment in the healthcare sector.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Belén Garijo López

Employees

74,846

Headquarters

Paris

Upcoming events

30 OCT

Earnings

Upcoming earnings report

38d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.